In-vitro assessment of lomefloxacin (SC-47111)--a new quinolone derivative.
The activity of lomefloxacin (SC-47111) was studied in vitro against 500 clinical isolates. Comparison was made with enoxacin and ciprofloxacin. Lomefloxacin was comparable in activity to enoxacin, but less active than ciprofloxacin. Most Gram-negative bacilli were susceptible, including several multi-resistant strains. Pseudomonas aeruginosa showed variable susceptibility. Streptococci, including Streptococcus pneumoniae, were generally the least susceptible organisms.